Merz Aesthetics® Introduces New BELOTERO® Syringe Offering Greater Precision, Comfort and Ease of Use

(BUSINESS WIRE) -- Merz Aesthetics, the world’s largest dedicated medical aesthetics business, announced today the launch of a new syringe for its category-leading hyaluronic acid (HA) brand BELOTERO^®*. The new syringe is ergonomically engineered to elevate the treatment experience, offering greater precision, comfort, and ease of use. The new syringe will launch first in Europe, and then will expand to markets worldwide.

“As the first region to introduce this innovation ahead of our global expansion, I’m proud to share this exciting milestone in BELOTERO^®’s history as a trusted leader in hyaluronic acid treatments,” said Gonzalo Mibelli, President EMEA region.

What is BELOTERO^®?

BELOTERO^® is a thoughtfully designed, comprehensive range of highly cohesive hyaluronic acid fillers, developed to deliver predictable, harmonious results through seamless tissue integration. The full portfolio offers tailored solutions to enhance facial features, improve skin quality, and visibly reduce signs of aging, all with long-lasting**, natural-looking outcomes.^2-4

BELOTERO^® recently marked 20 successful years in the aesthetics market, with over 18 million syringes sold worldwide, a true testament to its legacy.³

Smart Design. Precise Control. Same Trusted Formula.

“From a design perspective, the new BELOTERO^® syringe* delivers both aesthetics and functionality, particularly with its advanced haptics and ergonomic finger-grip,” said Dr. Tatjana Pavicic, a board-certified dermatologist in Munich, Germany. “The anti-slip, signature color-coded silicone surfaces enhance user experience, providing easy identification, practitioner comfort, and enhanced stability during procedures.”

With a patent-protected design developed exclusively for BELOTERO^®, the new syringe, with the same trusted formula, stands out in the global marketplace with several key improvements, such as:

• Ergonomic Design: The redesigned syringe offers a more comfortable grip, making handling easier during procedures.⁴

• Precision at Every Angle: Engineered for consistent syringe performance, the syringe adapts to various angles, providing greater control and stability.

• Improved Safety Design: An integrated Luer Lock system keeps the needle securely attached, supporting safer administration.

Clinically Validated and Recognized by Experts

“We are thrilled that our new BELOTERO^® syringe* has already been recognized by a panel of expert users for providing the volume control, adaptability and consistent handling we know our customers and patients are looking for,” said Alexis Stern, Global Chief Marketing Officer at Merz Aesthetics. “In fact, 93% of users rated the new BELOTERO^® syringe* as easy and intuitive.”⁴

The new BELOTERO^® syringe will launch starting with BELOTERO^® Balance^®, BELOTERO^® Soft, and BELOTERO^® Intense in Austria, Belgium, Netherlands, Luxembourg, Germany, Italy, Switzerland, Spain, Portugal, the United Kingdom, Ireland, and Malta, followed by a phased global rollout. All BELOTERO^® products with the current syringe remain available for use as indicated.

* Available for BELOTERO^® Balance, Intense, and Soft

** Depending on product used, effects duration ranges from 6 months to 18 months based on clinical data.

About Merz Aesthetics

Merz Aesthetics is a medical aesthetics business with a long history of empowering health care professionals, patients, and employees to live every day with confidence. We aim to help people around the world look, feel and live like the best versions of themselves — however they define it. Clinically proven, its product portfolio includes injectables and devices, devices designed to meet each patient’s needs with high quality standards. Being family owned for more than 115 years, Merz Aesthetics is known for building unique connections with customers who feel like family. Merz Aesthetics’ global headquarters is in Raleigh, N.C., USA, with a commercial presence in 90 countries worldwide. It is also a part of Merz Group, which was founded in 1908 and is based in Frankfurt, Germany. Learn more at merzaesthetics.com.

All BELOTERO^® products referred contain lidocaine, as BELOTERO^® without lidocaine has been discontinued, with the exception of BELOTERO^® Revive designed without lidocaine. For your information, BELOTERO^® – lidocaine and non-lidocaine share the same product specifications, with the key difference being the inclusion (or absence) of lidocaine.

Important BELOTERO^® Soft Lidocaine, BELOTERO^® Balance Lidocaine, and BELOTERO^® Intense Lidocaine Hyaluronic Acid Treatment Considerations (Regions to update based on local safety language)

BELOTERO^® Soft Lidocaine is an injectable biodegradable implant intended for filling of perioral fine lines. BELOTERO^® Soft Lidocaine is a device without an intended medical purpose. BELOTERO^® Soft Lidocaine is indicated for injection into the superficial to mid-dermis for treatment of perioral fine lines.

BELOTERO^® Balance Lidocaine is an injectable biodegradable implant intended for filling of facial wrinkles and folds as well as for lip enhancement. BELOTERO^® Balance Lidocaine is a device without an intended medical purpose. BELOTERO^® Balance Lidocaine is indicated for injection into the superficial to mid-dermis for treatment of naso-labial folds, marionette lines, perioral lines and oral commissures. BELOTERO^® Balance Lidocaine is indicated for submucosal or subcutaneous injection for lip enhancement.

BELOTERO^® Intense Lidocaine is an injectable biodegradable implant intended for filling of deep facial wrinkles and folds as well as to restore and enhance soft tissue volume. BELOTERO^® Intense Lidocaine is a device without an intended medical purpose. BELOTERO^® Intense Lidocaine is indicated for injection into the deep dermis for treatment of nasolabial folds and marionette lines. BELOTERO^® Intense Lidocaine is indicated for submucosal or subcutaneous injection for lip enhancement.

References

1. Fischer TC, et al. Facial Plast Surg. 2016 Jun;32(3):283-

2. Molliard S.G., et al. J Med Behav Biomed Mater. 2016;61:290-8.

3. Van Loghem, J. et al. Clin Cosm Inv Dermatol. 2021:14 1175-1

4. Data on File. (CE approval).

5. Data on file. 2021 Emergo Design Change Validation Report.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251102471476/en/